Peregrine Pharmaceuticals, Inc. Announces Participation at Upcoming Investor Conferences

Published: Feb 27, 2013

TUSTIN, CA--(Marketwire - February 26, 2013) -

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W. King, president and chief executive officer, will participate at the following investor conferences:

  • 33rd Annual Cowen Health Care Conference
    Tuesday, March 5, 2013, at 10:40am Eastern Standard Time
    Marriott Copley Hotel Boston, Massachusetts

  • 25th Annual ROTH Conference
    Monday, March 18, 2013, at 2:00pm Pacific Daylight Time
    The Ritz Carlton Hotel Dana Point, California

  • Stifel Nicolaus & Company Biotechnology Investor Day
    Wednesday, March 20, 2013
    San Francisco, California

Peregrine's presentations at the Cowen and Roth Conferences will be webcast live and available for replay until April 12, 2013 and April 25, 2013, respectively at:

About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256

Digg this    Bookmark with    Add to Newsvine


Back to news